Cellectar Biosciences, ITM announce supply agreement for Actinium-225.

Cellectar Biosciences and ITM Isotope Technologies Munich SE have entered into a supply agreement for Actinium-225 to support the clinical development of Cellectar's actinium-labeled phospholipid ether radiopharmaceutical candidates, including Phase 1-ready CLR 121225 for solid tumor treatment. Cellectar's proprietary PLE delivery platform enables targeted cancer cell eradication.

Cellectar Biosciences, Inc. (Nasdaq: CLRB) and ITM Isotope Technologies Munich SE (ITM) have entered into a supply agreement for Actinium-225 (Ac-225), a key isotope for radiopharmaceutical development. This agreement will support the clinical development of Cellectar's actinium-labeled phospholipid ether (PLE) radiopharmaceutical candidates, including CLR 121225, a Phase 1-ready compound for the treatment of solid tumors Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225^[1].

CLR 121225, an actinium-labeled PLE, is under investigation for various solid tumors, including pancreatic cancer. Cellectar's proprietary PLE delivery platform allows for the design and development of novel radiopharmaceuticals that can selectively target and eradicate cancer cells. ITM, with its two decades of experience in medical isotope manufacturing, will supply Cellectar with Ac-225 to ensure rapid and reliable delivery Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225^[1].

The scarcity of high-quality Ac-225 has hindered the advancement of research and development in this area. To overcome this challenge, Cellectar has constructed a network of Ac-225 suppliers, ensuring access to a sufficient supply. This agreement reflects ITM's strategic commitment to advancing global access to radiopharmaceuticals and supporting Cellectar's pipeline candidates Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225^[1].

ITM's Actineer™ Inc., a joint venture with Canadian Nuclear Laboratories, will produce the required quantities of Ac-225, which is crucial for meeting the growing demand for this critical isotope. The agreement underscores the importance of reliable, scalable production sites to support the development of innovative radiopharmaceutical therapies Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225^[1].

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary cancer treatments. Its product pipeline includes iopofosine I 131, CLR 121225, and CLR 121125, among others. ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225^[1].

This agreement is a significant milestone for Cellectar, as it supports the advancement of its pipeline and addresses the critical need for Ac-225 in the development of targeted alpha therapy for cancer patients.